SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 2006; 82: S4S8.
  • 2
    Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1997; 126: 275.
  • 3
    Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 16451652.
  • 4
    Seu P, Winston DJ, Holt CD, Kaldas F, Busuttil R. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seropositive donors. Transplantation 1997; 64: 16141617.
  • 5
    Gane E, Faouzi S, Valdecasas G, O'Grady J, Pescovitz M, Lyman S, Robinson C. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 17291733.
  • 6
    Winston DW, Busuttil RW. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus diseases in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 2004; 77: 305308.
  • 7
    Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 28112815.
  • 8
    Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611620.
  • 9
    Roche Pharmaceuticals. Valcyte (valganciclovir hydrochloride tablets) package insert 2006. Available at: http://www.rocheusa.com/products/valcyte. Accessed February 2009.
  • 10
    Arthurs SK, Eid AJ, Pederson RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR. Delayed onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007; 13: 17031709.
  • 11
    Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006; 12: 112116.
  • 12
    Slifkin M, Ruthazer R, Freeman R, Bloom J, Fitzmaurice S, Fairchild R, et al. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transpl 2005; 11: 15971602.
  • 13
    Hardinger KL, Schnitzler MA, Brennan DC, et al. Cytomegalovirus increases the rate of graft loss after liver transplantation. Am J Transplant 2003; 3(suppl 5): 523.
  • 14
    Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005; 79: 14771483.
  • 15
    Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, et al. Does valganciclovir hydrochloride (Valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc 2005; 37: 31823186.
  • 16
    Humar A, Mazzulli T, Moussa G, Razonable R, Paya C, Pescovitz M, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R− transplant recipients. Am J Transplant 2005; 5: 10651070.